{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:59:22Z","timestamp":1787003962724,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The\n                    <jats:bold>NAP<\/jats:bold>\n                    (\n                    <jats:bold>NAP<\/jats:bold>\n                    V\n                    <jats:underline>SIP<\/jats:underline>\n                    Q) sequence of activity-dependent neuroprotective protein (ADNP) contains the\n                    <jats:underline>SxIP<\/jats:underline>\n                    motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.\n                  <\/jats:p>","DOI":"10.1038\/srep16300","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T05:22:18Z","timestamp":1447132938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model"],"prefix":"10.1038","volume":"5","author":[{"given":"Sinaya","family":"Vaisburd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Shemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adva","family":"Yeheskel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illana","family":"Gozes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,10]]},"reference":[{"key":"BFsrep16300_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0140-6736(90)91520-K","volume":"336","author":"D St Clair","year":"1990","unstructured":"St Clair, D. et al. Association within a family of a balanced autosomal translocation with major mental illness. The Lancet 336, 13\u201316 (1990).","journal-title":"The Lancet"},{"key":"BFsrep16300_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neuroscience.2003.11.010","volume":"124","author":"CP Austin","year":"2004","unstructured":"Austin, C. P., Ky, B., Ma, L., Morris, J. A. & Shughrue, P. J. Expression of Disrupted-In-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 124, 3\u201310, 10.1016\/j.neuroscience.2003.11.010 (2004).","journal-title":"Neuroscience"},{"key":"BFsrep16300_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/schbul\/sbp133","volume":"36","author":"H Jaaro-Peled","year":"2010","unstructured":"Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. & Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull 36, 301\u2013313, 10.1093\/schbul\/sbp133 (2010).","journal-title":"Schizophr Bull"},{"key":"BFsrep16300_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.mcn.2013.01.006","volume":"54","author":"AM Lepagnol-Bestel","year":"2013","unstructured":"Lepagnol-Bestel, A. M., Kvajo, M., Karayiorgou, M., Simonneau, M. & Gogos, J. A. A Disc1 mutation differentially affects neurites and spines in hippocampal and cortical neurons. Mol Cell Neurosci 54, 84\u201392, 10.1016\/j.mcn.2013.01.006 (2013).","journal-title":"Mol Cell Neurosci"},{"key":"BFsrep16300_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00213-003-1761-y","volume":"174","author":"PJ Harrison","year":"2004","unstructured":"Harrison, P. J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 174, 151\u2013162, 10.1007\/s00213-003-1761-y (2004).","journal-title":"Psychopharmacology"},{"key":"BFsrep16300_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/01.wnr.0000175248.25535.f6","volume":"16","author":"KE Burdick","year":"2005","unstructured":"Burdick, K. E. et al. DISC1 and neurocognitive function in schizophrenia. Neuroreport 16, 1399\u20131402, 00001756-200508220-00028 [pii] (2005).","journal-title":"Neuroreport"},{"key":"BFsrep16300_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.mp.4002079","volume":"13","author":"MV Pletnikov","year":"2008","unstructured":"Pletnikov, M. V. et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatr 13, 173\u2013186, 10.1038\/sj.mp.4002079 (2008).","journal-title":"Mol Psychiatr"},{"key":"BFsrep16300_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/mp.2014.97","volume":"19","author":"S Oz","year":"2014","unstructured":"Oz, S. et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry 19, 1115\u20131124, 10.1038\/mp.2014.97 (2014).","journal-title":"Mol Psychiatry"},{"key":"BFsrep16300_CR9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2174\/138161211795589373","volume":"17","author":"INAP Gozes","year":"2011","unstructured":"Gozes, I. N. A. P. (davunetide) provides functional and structural neuroprotection. Current pharmaceutical design 17, 1040\u20131044 (2011).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep16300_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1471-4159.2006.03936.x","volume":"98","author":"I Divinski","year":"2006","unstructured":"Divinski, I., Holtser-Cochav, M., Vulih-Schultzman, I., Steingart, R. A. & Gozes, I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98, 973\u2013984 (2006).","journal-title":"J Neurochem"},{"key":"BFsrep16300_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nbd.2013.04.012","volume":"56","author":"Y Jouroukhin","year":"2013","unstructured":"Jouroukhin, Y. et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport. Neurobiol Dis 56, 79\u201394, 10.1016\/j.nbd.2013.04.012 (2013).","journal-title":"Neurobiol Dis"},{"key":"BFsrep16300_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.tcb.2012.05.005","volume":"22","author":"P Kumar","year":"2012","unstructured":"Kumar, P. & Wittmann, T. +TIPs: SxIPping along microtubule ends. Trends in Cell Biology 22, 418\u2013428, 10.1016\/j.tcb.2012.05.005 (2012).","journal-title":"Trends in Cell Biology"},{"key":"BFsrep16300_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cortex.2013.12.004","volume":"55","author":"KK Nicodemus","year":"2014","unstructured":"Nicodemus, K. K. et al. Category fluency, latent semantic analysis and schizophrenia: a candidate gene approach. Cortex; a journal devoted to the study of the nervous system and behavior 55, 182\u2013191, 10.1016\/j.cortex.2013.12.004 (2014).","journal-title":"Cortex; a journal devoted to the study of the nervous system and behavior"},{"key":"BFsrep16300_CR14","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/hmg\/dds111","volume":"21","author":"RM Walker","year":"2012","unstructured":"Walker, R. M. et al. The DISC1 promoter: characterization and regulation by FOXP2. Hum Mol Genet 21, 2862\u20132872, 10.1093\/hmg\/dds111 (2012).","journal-title":"Hum Mol Genet"},{"key":"BFsrep16300_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/35097076","volume":"413","author":"CSL Lai","year":"2001","unstructured":"Lai, C. S. L., Fisher, S. E., Hurst, J. A., Vargha-Khadem, F. & Monaco, A. P. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 413, 519\u2013523, (2001).","journal-title":"Nature"},{"key":"BFsrep16300_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1086\/430841","volume":"76","author":"KD MacDermot","year":"2005","unstructured":"MacDermot, K. D. et al. Identification of FOXP2 Truncation as a Novel Cause of Developmental Speech and Language Deficits. The American Journal of Human Genetics 76, 1074\u20131080 (2005).","journal-title":"The American Journal of Human Genetics"},{"key":"BFsrep16300_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.schres.2004.05.012","volume":"73","author":"J Sanjuan","year":"2005","unstructured":"Sanjuan, J. et al. FOXP2 polymorphisms in patients with schizophrenia. Schizophr Res 73, 253\u2013256, 10.1016\/j.schres.2004.05.012 (2005).","journal-title":"Schizophr Res"},{"key":"BFsrep16300_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/01.ypg.0000185029.35558.bb","volume":"16","author":"J Sanjuan","year":"2006","unstructured":"Sanjuan, J. et al. Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiatr Genet 16, 67\u201372, 10.1097\/01.ypg.0000185029.35558.bb (2006).","journal-title":"Psychiatr Genet"},{"key":"BFsrep16300_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1471-2350-11-114","volume":"11","author":"A Tolosa","year":"2010","unstructured":"Tolosa, A. et al. FOXP2 gene and language impairment in schizophrenia: association and epigenetic studies. BMC Med Genet 11, 114, 10.1186\/1471-2350-11-114 (2010).","journal-title":"BMC Med Genet"},{"key":"BFsrep16300_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/15622975.2011.615860","volume":"14","author":"T Li","year":"2013","unstructured":"Li, T. et al. FoxP2 is significantly associated with schizophrenia and major depression in the Chinese Han population. World J Biol Psychiatry 14, 146\u2013150, 10.3109\/15622975.2011.615860 (2013).","journal-title":"World J Biol Psychiatry"},{"key":"BFsrep16300_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1364-6613(03)00104-9","volume":"7","author":"GF Marcus","year":"2003","unstructured":"Marcus, G. F. & Fisher, S. E. FOXP2 in focus: what can genes tell us about speech and language? Trends in cognitive sciences 7, 257\u2013262 (2003).","journal-title":"Trends in cognitive sciences"},{"key":"BFsrep16300_CR22","doi-asserted-by":"crossref","unstructured":"Gozes, I. et al. Novel Tubulin and Tau Neuroprotective Fragments Sharing Structural Similarities with the Drug Candidate NAP (Davuentide). J Alzheimers Dis, V01L482628837064 (2014).","DOI":"10.3233\/JAD-131664"},{"key":"BFsrep16300_CR23","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U","volume":"38","author":"SJ Teague","year":"1999","unstructured":"Teague, S. J., Davis, A. M., Leeson, P. D. & Oprea, T. The Design of Leadlike Combinatorial Libraries. Angewandte Chemie 38, 3743\u20133748 (1999).","journal-title":"Angewandte Chemie"},{"key":"BFsrep16300_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9","volume":"8","author":"M Congreve","year":"2003","unstructured":"Congreve, M., Carr, R., Murray, C. & Jhoti, H. A \u2018rule of three\u2019 for fragment-based lead discovery? Drug discovery today 8, 876\u2013877 (2003).","journal-title":"Drug discovery today"},{"key":"BFsrep16300_CR25","doi-asserted-by":"publisher","first-page":"28531","DOI":"10.1074\/jbc.M403197200","volume":"279","author":"I Divinski","year":"2004","unstructured":"Divinski, I., Mittelman, L. & Gozes, I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279, 28531\u201328538 (2004).","journal-title":"J Biol Chem"},{"key":"BFsrep16300_CR26","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","volume":"20","author":"L Rajagopal","year":"2014","unstructured":"Rajagopal, L., Massey, B. W., Huang, M., Oyamada, Y. & Meltzer, H. Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20, 5104\u20135114 (2014).","journal-title":"Curr Pharm Des"},{"key":"BFsrep16300_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.peptides.2010.04.011","volume":"31","author":"A Merenlender-Wagner","year":"2010","unstructured":"Merenlender-Wagner, A., Pikman, R., Giladi, E., Andrieux, A. & Gozes, I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse\u2013a microtubule-deficient model of schizophrenia. Peptides 31, 1368\u20131373, 10.1016\/j.peptides.2010.04.011 (2010).","journal-title":"Peptides"},{"key":"BFsrep16300_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0166-4328(00)00301-6","volume":"117","author":"BM Cooke","year":"2000","unstructured":"Cooke, B. M., Chowanadisai, W. & Breedlove, S. M. Post-weaning social isolation of male rats reduces the volume of the medial amygdala and leads to deficits in adult sexual behavior. Behav Brain Res 117, 107\u2013113 (2000).","journal-title":"Behav Brain Res"},{"key":"BFsrep16300_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00213-013-3011-2","volume":"228","author":"AL McIntosh","year":"2013","unstructured":"McIntosh, A. L., Ballard, T. M., Steward, L. J., Moran, P. M. & Fone, K. C. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology (Berl) 228, 31\u201342, 10.1007\/s00213-013-3011-2 (2013).","journal-title":"Psychopharmacology (Berl)"},{"key":"BFsrep16300_CR30","doi-asserted-by":"publisher","first-page":"e93966","DOI":"10.1371\/journal.pone.0093966","volume":"9","author":"F Zhu","year":"2014","unstructured":"Zhu, F. et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One 9, e93966, 10.1371\/journal.pone.0093966 (2014).","journal-title":"PLoS One"},{"key":"BFsrep16300_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"DA Lewis","year":"2000","unstructured":"Lewis, D. A. & Lieberman, J. A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28, 325\u2013334, Doi 10.1016\/S0896-6273(00)00111-2 (2000).","journal-title":"Neuron"},{"key":"BFsrep16300_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1176\/ajp.153.3.321","volume":"153","author":"MF Green","year":"1996","unstructured":"Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153, 321\u2013330, 10.1176\/ajp.153.3.321 (1996).","journal-title":"Am J Psychiatry"},{"key":"BFsrep16300_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.schres.2011.11.001","volume":"136","author":"DC Javitt","year":"2012","unstructured":"Javitt, D. C. et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136, 25\u201331, S0920-9964(11)00564-0 (2012).","journal-title":"Schizophr Res"},{"key":"BFsrep16300_CR34","doi-asserted-by":"publisher","first-page":"e1168","DOI":"10.4088\/JCP.12m07642","volume":"73","author":"Y Geffen","year":"2012","unstructured":"Geffen, Y., Keefe, R., Rabinowitz, J., Anand, R. & Davidson, M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. The Journal of clinical psychiatry 73, e1168\u20131174, 10.4088\/JCP.12m07642 (2012).","journal-title":"The Journal of clinical psychiatry"},{"key":"BFsrep16300_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer, H. Y. & McGurk, S. R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia bulletin 25, 233\u2013255 (1999).","journal-title":"Schizophrenia bulletin"},{"key":"BFsrep16300_CR36","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1097\/00004714-199502001-00004","volume":"15","author":"L Farde","year":"1995","unstructured":"Farde, L. et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15, 19S\u201323S (1995).","journal-title":"J Clin Psychopharmacol"},{"key":"BFsrep16300_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neulet.2003.12.005","volume":"361","author":"RN Alcalay","year":"2004","unstructured":"Alcalay, R. N., Giladi, E., Pick, C. G. & Gozes, I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361, 128\u2013131 (2004).","journal-title":"Neurosci Lett"},{"key":"BFsrep16300_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pbb.2010.02.005","volume":"95","author":"T Sun","year":"2010","unstructured":"Sun, T., He, W., Hu, G. & Li, M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 95, 298\u2013307, 10.1016\/j.pbb.2010.02.005 (2010).","journal-title":"Pharmacol Biochem Behav"},{"key":"BFsrep16300_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.2420","volume":"29","author":"T Cabaleiro","year":"2014","unstructured":"Cabaleiro, T. et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of risperidone in healthy volunteers. Human psychopharmacology 29, 459\u2013469, 10.1002\/hup.2420 (2014).","journal-title":"Human psychopharmacology"},{"key":"BFsrep16300_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4419-1599-3_9","volume":"665","author":"H Takahashi","year":"2009","unstructured":"Takahashi, H., Takahashi, K. & Liu, F. C. FOXP genes, neural development, speech and language disorders. Adv Exp Med Biol 665, 117\u2013129 (2009).","journal-title":"Adv Exp Med Biol"},{"key":"BFsrep16300_CR41","doi-asserted-by":"publisher","first-page":"27488","DOI":"10.1074\/jbc.M100636200","volume":"276","author":"W Shu","year":"2001","unstructured":"Shu, W., Yang, H., Zhang, L., Lu, M. M. & Morrisey, E. E. Characterization of a new subfamily of winged-helix\/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. The Journal of biological chemistry 276, 27488\u201327497, 10.1074\/jbc.M100636200 (2001).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep16300_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.schres.2007.11.018","volume":"99","author":"SH Fatemi","year":"2008","unstructured":"Fatemi, S. H. et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophrenia research 99, 56\u201370, 10.1016\/j.schres.2007.11.018 (2008).","journal-title":"Schizophrenia research"},{"key":"BFsrep16300_CR43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/npp.2013.23","volume":"38","author":"LF Jarskog","year":"2013","unstructured":"Jarskog, L. F. et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 38, 1245\u20131252, 10.1038\/npp.2013.23 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"BFsrep16300_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cell.2009.04.065","volume":"138","author":"S Honnappa","year":"2009","unstructured":"Honnappa, S. et al. An EB1-binding motif acts as a microtubule tip localization signal. Cell 138, 366\u2013376, 10.1016\/j.cell.2009.04.065 (2009).","journal-title":"Cell"},{"key":"BFsrep16300_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/ci030304f","volume":"44","author":"H Sun","year":"2004","unstructured":"Sun, H. A universal molecular descriptor system for prediction of logP, logS, logBB and absorption. Journal of chemical information and computer sciences 44, 748\u2013757, 10.1021\/ci030304f (2004).","journal-title":"Journal of chemical information and computer sciences"},{"key":"BFsrep16300_CR46","doi-asserted-by":"publisher","first-page":"W270","DOI":"10.1093\/nar\/gkr366","volume":"39","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39, W270\u2013277, 10.1093\/nar\/gkr366 (2011).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep16300_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/prot.10397","volume":"52","author":"D Schneidman-Duhovny","year":"2003","unstructured":"Schneidman-Duhovny, D. et al. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 52, 107\u2013112, 10.1002\/prot.10397 (2003).","journal-title":"Proteins"},{"key":"BFsrep16300_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1385\/jmn:28:3:303","volume":"28","author":"M Holtser-Cochav","year":"2006","unstructured":"Holtser-Cochav, M., Divinski, I. & Gozes, I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP and D-SAL. Journal of molecular neuroscience: MN 28, 303\u2013307, 10.1385\/jmn:28:3:303 (2006).","journal-title":"Journal of molecular neuroscience: MN"},{"key":"BFsrep16300_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pbb.2006.08.007","volume":"85","author":"N de Bruin","year":"2006","unstructured":"de Bruin, N. & Pouzet, B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85, 253\u2013260, S0091-3057(06)00264-4 (2006).","journal-title":"Pharmacol Biochem Behav"},{"key":"BFsrep16300_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","volume":"14","author":"S Pellow","year":"1985","unstructured":"Pellow, S., Chopin, P., File, S. E. & Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14, 149\u2013167 (1985).","journal-title":"J Neurosci Methods"},{"key":"BFsrep16300_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0091-3057(93)90492-C","volume":"44","author":"D Treit","year":"1993","unstructured":"Treit, D., Menard, J. & Royan, C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44, 463\u2013469 (1993).","journal-title":"Pharmacol Biochem Behav"},{"key":"BFsrep16300_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","volume":"34","author":"N Shiryaev","year":"2009","unstructured":"Shiryaev, N. et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34, 381\u2013388, 10.1016\/j.nbd.2009.02.011 (2009).","journal-title":"Neurobiol Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep16300","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T08:17:28Z","timestamp":1672906648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep16300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,21]]}},"alternative-id":["BFsrep16300"],"URL":"https:\/\/doi.org\/10.1038\/srep16300","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,10]]},"assertion":[{"value":"20 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16300"}}